CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) traded down 2.1% on Tuesday . The company traded as low as $0.2230 and last traded at $0.2304. 2,577,568 shares were traded during mid-day trading, an increase of 39% from the average daily volume of 1,859,706 shares. The stock had previously closed at $0.2354.
CytoDyn Trading Down 2.1%
The firm’s 50-day simple moving average is $0.30 and its 200 day simple moving average is $0.28. The stock has a market cap of $317.31 million, a P/E ratio of -7.68 and a beta of 1.16.
About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Read More
- Five stocks we like better than CytoDyn
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
